ImmunoGen, Inc. has announced that its platinum-resistant ovarian cancer drug ELAHERE (mirvetuximab soravtansine-gynx) has been granted FDA accelerated approval. This first FDA antibody-drug ...

ImmunoGenAlmost four years after backing out of an antibody-drug conjugate (ADC) alliance with ImmunoGen, Eli Lilly has come back to the table with a new, wide-ranging deal worth up to $1.7 billion.

Despite the death of its golden goose, AbbVie expects to achieve high single-digit compound annual sales growth to the end of ...

As LB Pharmaceuticals enters a pivotal stage of growth, the additions of Gad and Richard to our leadership team reinforce our ability to execute on our ambitious clinical and regulatory goals,” said ...

近日，艾伯维公布了2024全年及第四季度财报，数据显示，其全年总营收达563.34亿美元，以强劲势头为2025年的持续增长奠定了坚实基础。在面临修美乐专利悬崖的挑战时， ...

Advanced Ovarian Cancer Pipeline Insights LAS VEGAS, NV, UNITED STATES, February 12, 2025 /EINPresswire / -- As per DelveInsight's assessme ...

从榜单能看出，2024 年全球药物市场可真是 “多点开花”，肿瘤、自身免疫、代谢这些领域特别突出。生物药在畅销药里占了大头，是市场上的 “主力军” 。而且，新技术不断有突破，很多药物都拓展出了新的适用病症。就拿 GLP - 1 类药物来说，除了降糖，还能用来减重、保护心血管，未来发展的潜力大着呢。不过，生物类似药越来越多，这给原研药市场带来了挑战。好在新的创新药物也在不断冒出来，给市场增添了新活力 ...

Learn how analytical methodologies can be used to identify RSV pre- and post-fusion proteins for vaccine development.

Audit reveals deep inefficiencies at premier research institute, with futuristic projects worth ₹21 crore left unfinished ...

当地时间2月12日，艾伯维（NYSE：ABBV）与Xilio Therapeutics（NASDAQ：XLO）宣布达成一项合作和选择性许可协议，双方将利用Xilio的专有技术，共同开发新型肿瘤激活、基于抗体的免疫疗法，其中包括掩蔽型T细胞接合器（TCE）。

While the company is unable to disclose specific details about the interim analysis due to regulatory requirements set forth by the U.S. Food and Drug Administration (FDA), MimiVax remains confident ...